Annual Drug Patent Expirations for SYNJARDY+XR
Synjardy Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug and one Paragraph IV challenge.
SYNJARDY XR drug price trends.
Drug patent litigation for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. One supplier is listed for this compound. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
